Minaris Regenerative Medicine
Renate Sporrer currently serves as the Chief Operating Officer at Minaris Regenerative Medicine since June 2021 and has held various significant roles in the biopharmaceutical industry. Prior to this, Renate Sporrer was Site Quality Head for Roche in Basel from October 2019 to June 2021. Experience includes serving as Quality Director at Polpharma Biologics S.A. and Polpharma Biologics from January 2019 to July 2019 and July 2016 to January 2019, respectively. Renate Sporrer also worked at Sandoz GmbH as Head QA from October 2013 to June 2016 and as Head QA Compliance at Novartis from February 2012 to September 2013. Early career contributions at Sandoz GmbH included heading the Cell Culture Manufacturing Plant and overseeing Quality Management from April 2006 to January 2012.
This person is not in any offices
Minaris Regenerative Medicine
Minaris Regenerative Medicine is a global contract development and manufacturing organization for the production of cell and gene therapy products. We offer our clients clinical and commercial manufacturing services, development solutions, and technologies. With more than 20 years’ experience in the field of regenerative medicine, we are trusted partner ensuring scalability, delivering high quality results, and achieving cost effective manufacturing. Our state-of-the-art facilities in the United States, Europe, and Asia, as well as our committed employees, enable us to supply patients worldwide with lifechanging therapies. At Minaris, we are creating cell therapy miracles together. Minaris Regenerative Medicine is wholly owned by the Resonac Group.